Identifying relevant factors influencing cancer-related fatigue in patients with diffuse large B-cell lymphoma during chemotherapy

Table 1 Demographic and clinical characteristics of study-eligible patients

Characteristics	Eligible, n = 62
Sex
Male	29
Female	33
Age in years
≤ 65	49
> 65	13
Education
High school or less	23
College	20
Bachelor’s degree	15
Graduate degree	4
ECOG performance status
< 2	8
≥ 2	7
BMI in kg/m2, median (IQR)	25.4 (22.2-28.7)
High serum LDH	9
High serum β2m	11

BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; LDH: Lactate dehydrogenase; β2m: β2-microglobulin.

Table 2 Psychological symptom scores in patients with diffuse large B-cell lymphoma during chemotherapy

Item	Eligible, n = 62	Score
Restless sleep	58 (93.55)	4.51 ± 1.38
Sadness	57 (91.94)	4.77 ± 1.40
Forgetfulness	50 (80.65)	3.48 ± 1.12
Distress	58 (93.55)	4.53 ± 1.37
Numbness	30 (48.39)	3.47 ± 1.08

Data are n (%).

Table 3 Pittsburgh Sleep Quality Index and Five-Facet Mindfulness Questionnaire-Short Form of patients with diffuse large B-cell lymphoma during chemotherapy

Assessment measure	Scores
PSQI	10.49 ± 1.28
FFMQ-SF	49.85 ± 10.67

PSQI: Pittsburgh Sleep Quality Index; FFMQ-SF: Five-Facet Mindfulness Questionnaire-Short Form.

Table 4 Cancer-related fatigue status of patients with diffuse large B-cell lymphoma, n = 62

Dimension	Average score	Mild fatigue, n (%)	Moderate fatigue, n (%)	Severe fatigue, n (%)
Behavior fatigue	6.57 ± 2.43	18 (29.03)	35 (56.45)	9 (14.52)
Emotional fatigue	5.25 ± 2.14	15 (24.19)	29 (46.78)	34 (29.03)
Perceived fatigue	6.39 ± 2.36	20 (32.26)	32 (51.61)	10 (16.13)
Cognitive fatigue	5.37 ± 2.48	25 (40.32)	21 (33.87)	16 (25.81)
Total CRF score	5.74 ± 2.51	24 (38.71)	26 (41.94)	12 (19.35)

CRF: Cancer-related fatigue.

Table 5 Univariate analysis of cancer-related fatigue in patients with diffuse large B-cell lymphoma

Influencing factors	Eligible, n = 62	Average PFS score	P value
Sex			0.543
Male	29	5.44 ± 2.32
Female	33	5.74 ± 2.20
Age in years			0.095
≤ 65	49	4.59 ± 1.25
> 65	13	5.15 ± 2.42
Marital status			0.206
Married	21	5.57 ± 2.34
Unmarried	40	5.95 ± 2.53
Others	1	6.54 ± 2.32
Education			0.390
High school or less	23	4.39 ± 1.60
College	20	4.37 ± 1.38
Bachelor’s degree	15	5.07 ± 2.21
Graduate degree	4	5.93 ± 2.52
Self-efficacy level	26		0.031
High	26	4.66 ± 1.71
Medium	9	5.56 ± 2.30
Low		5.90 ± 2.51
Anxiety and depression degree			0.033
Mild	20	4.72 ± 1.32
Moderate	29	5.50 ± 2.53
Severe	13	5.97 ± 2.85
Tumor staging			0.001
Stage I	25	4.34 ± 1.55
Stage II	14	5.64 ± 2.19
Stage III	13	5.82 ± 2.44
Stage IV	10	6.78 ± 3.13
Chemotherapy cycle			0.006
First cycle	23	4.09 ± 1.13
Second cycle	19	4.52 ± 1.40
Third cycle	11	5.72 ± 2.37
Fourth cycle	9	6.46 ± 3.50
Pain degree			0.004
Mild	15	4.54 ± 1.75
Moderate	37	5.48 ± 2.44
Severe	10	6.31 ± 3.47

Table 6 Cancer-related fatigue-related symptoms during chemotherapy in the study patients

Items	Eligible, n = 62	Score
Fatigue	59 (95.16)	4.48 ± 1.47
Pain	51 (82.26)	4.42 ± 1.48
Dry mouth	55 (88.71)	4.35 ± 1.32
Lethargy	54 (87.10)	4.08 ± 1.34
Shortness of breath	28 (45.16)	3.52 ± 1.16

Data are n (%).

Table 7 Perceptual control scores in patients with diffuse large B-cell lymphoma during chemotherapy

Items	Score
Cancer experience
Personal experience	13.71 ± 1.98
Social experience	24.01 ± 3.02
Emotional experience	21.51 ± 3.12
Cancer efficacy
Personal efficacy	15.71 ± 4.66
Collective efficacy	18.28 ± 4.72
Medical care efficacy	11.63 ± 2.03

Table 8 Factors influencing cancer-related fatigue in patients with diffuse large B-cell lymphoma during chemotherapy

Factor	Regression coefficient	Wald χ2 value	P value	OR
Tumor staging	0.459	5.440	0.015	1.583
Chemotherapy cycle	0.233	4.629	0.003	1.339
Self-efficacy level	0.559	8.429	0.004	1.274
Anxiety and depression level	0.460	8.340	0.001	1.674

OR: Odds ratio.